How should a rash that develops during intravenous (IV) antibiotic therapy be evaluated and managed?

Evaluation and Management of Rash During IV Antibiotic Therapy

Immediately assess the severity of the rash to determine if the antibiotic must be stopped—discontinue the IV antibiotic immediately if there are any signs of severe cutaneous adverse reactions including vesicles, skin detachment, mucosal involvement, facial edema, pustules, or systemic symptoms (fever >38.5°C, organ involvement). 1

Severity Classification

The first critical step is determining whether this is a severe or non-severe reaction, as this dictates immediate management:

Severe Reactions (STOP antibiotic immediately):

• Skin detachment, vesicles, or grey-violaceous lesions (Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis)
• Painful or burning skin with mucosal erosions
• Pustular exanthema (Acute Generalized Exanthematous Pustulosis)
• Maculopapular rash with systemic involvement: fever >38.5°C, organ dysfunction, eosinophilia, abnormal liver/kidney function (DRESS syndrome)
• Anaphylaxis signs: respiratory compromise, hypotension, angioedema, or multi-system involvement
• Purpura (vasculitis) 1

Non-Severe Reactions (May continue with monitoring):

• Isolated maculopapular exanthema without organ involvement
• Urticaria alone without respiratory or systemic symptoms
• Localized erythema, pruritus, or warmth 1

Differential Diagnosis: True Allergy vs. Viral Exanthem

A critical pitfall is misattributing viral rashes to antibiotic allergy, particularly in children with concurrent infections. This leads to unnecessary lifelong antibiotic avoidance.

Key distinguishing features:

Viral exanthem (not true drug allergy):

• Rash appears 3-7 days after starting antibiotics during treatment for upper respiratory infection
• Absence of eosinophilia on laboratory testing
• Prominent midface edema with maculopapular rash
• Rapid resolution (2-5 days) after antibiotic discontinuation
• Low RegiSCAR score (2-3)
• Confirmation of viral infection (EBV, other respiratory viruses) 2, 3, 4

True antibiotic hypersensitivity:

• Presence of eosinophilia
• Progressive symptoms despite stopping antibiotic
• Higher RegiSCAR score (≥4)
• Positive skin testing or drug provocation test 2, 3

Special Consideration: EBV Infection

The classic teaching that 80-100% of patients with EBV develop rash with aminopenicillins is outdated. Recent evidence shows the actual incidence is only 16-20%, and many of these are viral rashes, not true drug allergy 3. When tested, only 30% had confirmed drug hypersensitivity 3. This means 70% of patients labeled as "penicillin allergic" after EBV infection are incorrectly labeled.

Management Algorithm

For Severe Reactions:

1. Stop IV antibiotic immediately
2. Administer systemic corticosteroids (0.5-2 mg/kg/day, taper over 4-6 weeks for severe reactions) 5
3. Switch to alternative antibiotic class with no cross-reactivity
4. Document as contraindicated for future use
5. Consider allergy/immunology consultation 1

For Non-Severe Reactions:

1. Obtain detailed history: timing of rash onset, concurrent symptoms, infection type
2. Check laboratory tests: CBC with differential (eosinophilia?), liver/kidney function
3. Assess for viral infection: EBV serology, respiratory viral panel if indicated
4. If viral infection confirmed and no eosinophilia: Consider continuing antibiotic with close monitoring, as this may be viral exanthem 2, 3
5. If true drug allergy suspected: Stop antibiotic, switch to alternative agent
6. Refer for allergy testing after resolution to confirm or exclude drug hypersensitivity before permanent labeling 1

Critical Pitfalls to Avoid

• Do not permanently label patients as "antibiotic allergic" without confirmatory testing, especially in children with concurrent viral infections—this leads to unnecessary use of broader-spectrum, more toxic, and expensive alternatives 3, 6
• Do not assume all rashes during antibiotic therapy are drug allergies—up to 72% of children with rashes during infection do not develop rash when given the same antibiotic while healthy 6
• Do not miss early signs of severe cutaneous adverse reactions—facial edema, mucosal involvement, and fever are red flags requiring immediate discontinuation 1
• Watch for extravasation with certain IV antibiotics (particularly nafcillin), which can cause cutaneous necrosis mimicking allergic reaction 7

Post-Resolution Follow-Up

All patients with suspected antibiotic allergy should undergo formal allergy evaluation including skin testing and/or drug provocation testing when clinically stable. This prevents inappropriate lifelong avoidance of first-line antibiotics and reduces unnecessary use of broad-spectrum alternatives 1, 8.

For patients with confirmed IgE-mediated allergy requiring beta-lactam therapy for life-threatening infections, rapid IV desensitization is safe and effective when performed in monitored settings 8.